Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 14 2 2020 04 07 130 139 EN Mehdi Mohammadi Kanesbi Cancer Molecular Pathology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran Lida Jarahi Department of Community Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran Mohammad Reza Keramati Cancer Molecular Pathology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran 2019 08 02 2020 01 16 Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia (AML). APL is famed with some special blood coagulation disorders such as disseminated intravascular coagulation (DIC). The therapeutic methods of APL contain All Trans Retinoic Acid (ATRA), arsenic trioxide (ATO) or/and chemotherapy. Many studies have been done on APL blood disorders and its treatment. These studies have shown different results. In this systematic article, we tried to review the effect of ATO therapy with or without ATRA and chemotherapy on DIC parameters (D.dimer, Prothrombin Time, Activated Partial Thrombin Time, Platelet count) in APL patients. The result of included studies demonstrated that although ATO can reduce the number of malignant cells in the bone marrow and peripheral blood, it does not have enough potential to attenuate the danger of high score DIC that is usual in APL patients and should be better to be used with other therapeutic methods.   https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/1163 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/1163/823